Licensing

Our specialist healthcare team, with backgrounds in the life sciences, understand the complexities of valuations and deal structures that are unique to licensing deals in pharma and biotech and are with our clients every step of the way.

We support clients with:

- In-licensing
- Out-licensing
- Drug licensing
- Facility licensing

Our Latest Deals

Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Jun 2021
has been acquired by
May 2021
has been acquired by
a Behrman Capital-backed company
May 2021
has formed a strategic alliance with
Apr 2021
has invested in
Mar 2021
has acquired
Mar 2021
has licensed the patents and know-how to its Crystalomics Formulation Technology to
Mar 2021
has invested in

Results. Great people creating great outcomes, together.

Latest Insights

Reports
19th October 2021

The Technology Services Perspective – Q3 2021

Deal activity this quarter continues to be driven by strong confidence in acquiring capability in next-gen, modernisation and cloud-first tech stacks, and premium services. Equally, capturing the end-to-end digital transformation value chain continues to be a key M&A theme to become the strategic operator and engineering partner of choice for large-scale budgets. Public tech companies […]

Reports
19th October 2021

The CyberScope – Q3 2021

Following the COVID-19 pandemic, we continue to see more companies using applications deployed on the cloud and an increasing need for cloud security and zero-trust network access solutions. Expansion of attack surfaces, sophisticated ransomware attacks and publicised security incidents continue to accelerate demand for next-gen security and proactive risk management. Q3 2021 finished strongly with […]

Reports
19th October 2021

The Enterprise Stack – Q3 2021

Following a strong Q2, the path to recovery from the global pandemic is increasingly clear on account of re-opening economies, record-breaking stock markets and an abundant supply of cheap capital fueling investor appetite. Deal making surged in Q3 with volumes up more than 20% on Q2 2021. The quarter witnessed c.500 transactions to further accelerate […]